Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations

Yu, Yanke; Lin, Jian; Muto, Chieko; Li, Yinhua; Mori, Yuko; Mittapalli, Rajendar K; Tse, Susanna; Liu, Jian; Ge, Bei Kang; Liu, Jing

doi:10.7150/ijms.65040



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2021; 18(16):3718-3727. doi:10.7150/ijms.65040 This issue Cite

Research Paper

Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations

Yanke Yu^1✉, Jian Lin², Chieko Muto³, Yinhua Li³, Yuko Mori³, Rajendar K Mittapalli¹, Susanna Tse², Jian Liu⁴, Bei Kang Ge⁴, Jing Liu^2✉

1. Pfizer Inc, La Jolla, CA, USA.
2. Pfizer Inc, Groton, CT, USA.
3. Pfizer R&D Japan, Tokyo, Japan.
4. Pfizer Investment Co., LTD, China.

Citation:

Yu Y, Lin J, Muto C, Li Y, Mori Y, Mittapalli RK, Tse S, Liu J, Ge BK, Liu J. Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations. Int J Med Sci 2021; 18(16):3718-3727. doi:10.7150/ijms.65040. https://www.medsci.org/v18p3718.htm

Other styles

Abstract

The objective for the present analyses was to evaluate the utility of physiologically-based pharmacokinetic (PBPK) modeling for prediction of the pharmacokinetics (PK) in Chinese and Japanese populations with a panel of Pfizer internal compounds. Twelve compounds from Pfizer internal development pipeline with available Westerner PK data and available PK data in at least one of the subpopulations of Japanese and Chinese populations were identified and included in the current analysis. These selected compounds represent various elimination pathways across different therapeutic areas. The Simcyp^® PBPK simulator was used to develop and verify the PBPK models of individual compounds. The developed models for these compounds were verified by using the clinical PK data in Westerners. The verified PBPK models were further used to predict the PK of these compounds in Chinese and Japanese populations and the predicted PK parameters were compared with the observed PK parameters. Ten of the 12 compounds had PK data in Chinese, and all the 12 compounds had PK data in Japanese. In general, the PBPK models performed well in predicting PK in Chinese and Japanese, with 8 of 10 drugs in Chinese and 7 of 12 drugs in Japanese has AAFE values less than 1.25-fold. PBPK-guided predictions of the relative PK difference were successful for 75% and 50%, respectively, between Chinese and Western and between Japanese and Western of the tested drugs using 0.8-1.25 as criteria. In conclusion, well verified PBPK models developed using data from Westerners can be used to predict the PK in Chinese and Japanese populations.

Keywords: PBPK, Chinese, Japanese, Modeling & Simulation, Ethnic PK

Citation styles

APA

Yu, Y., Lin, J., Muto, C., Li, Y., Mori, Y., Mittapalli, R.K., Tse, S., Liu, J., Ge, B.K., Liu, J. (2021). Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations. International Journal of Medical Sciences, 18(16), 3718-3727. https://doi.org/10.7150/ijms.65040.

ACS

Yu, Y.; Lin, J.; Muto, C.; Li, Y.; Mori, Y.; Mittapalli, R.K.; Tse, S.; Liu, J.; Ge, B.K.; Liu, J. Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations. Int. J. Med. Sci. 2021, 18 (16), 3718-3727. DOI: 10.7150/ijms.65040.

NLM

CSE

Yu Y, Lin J, Muto C, Li Y, Mori Y, Mittapalli RK, Tse S, Liu J, Ge BK, Liu J. 2021. Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations. Int J Med Sci. 18(16):3718-3727.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.